Axitinib

Licensed by Pfizer Catalog No.S1005 Synonyms: AG 013736

Axitinib Chemical Structure

Molecular Weight(MW): 386.47

Axitinib is a multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ and c-Kit with IC50 of 0.1 nM, 0.2 nM, 0.1-0.3 nM, 1.6 nM and 1.7 nM in Porcine aorta endothelial cells, respectively.

Size Price Stock Quantity  
In DMSO USD 64 In stock
USD 70 In stock
USD 120 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • Representative confocal image (10 x objective) of individual spheroids fixed, sectioned, and then stained for vimentin (green) and DNA (DAPI, blue). Vimentin protein expression from sections quantitated from multiple replicate spheroid treatments with U0126 and axitinib using ImageJ software.

    J Biomol Screen, 2011,16: 141-154. Axitinib purchased from Selleck.

    VimPro-Fluc activity in spheroids after 72-h treatment with control modulators of epithelial-mesenchymal transition (EMT) normalized to spheroid viability and compared to vimentin protein expression using Western blot analysis.

    J Biomol Screen, 2011,16: 141-154. Axitinib purchased from Selleck.

  • Secondary assay development. The invasive potential of MDA-MB-231 spheroids was measured using modified Boyden chambers coated with Matrigel™. Invading cells were fixed, stained with DAPI, and quantified by fluorescence microscopy using 5 random fields per filter insert in triplicate. U0126, PF2341066, axitinib, and PKC412 inhibited the invasive potential of MDA-MB-231 spheroids by ~90% as compared to untreated spheroids (UT). ***p ≤ 0.001. IGF1R and dasatinib displayed no statistical difference as compared to UT MDA-MB-231 spheroids.

    J Biomol Screen 2011 16, 141-154. Axitinib purchased from Selleck.

    Axitinib treatment blocks VEGFR2 phosphorylation.

    HUVECs were starved O/N in EBM-2 basal medium with 1% FBS and antibiotic. Cells were pre-treated with Axitinib at 0.1, 1 and 10 nM concentrations. VEGF stimulation was 50 ng/ml for 10 minutes before cells were collected and protein isolated for immunoprecipitation with VEGFR2 followed by immunoblotting with VEGFR-2 and phospho-VEGFR-2.

     

     

    Dr. Cheri Pasch of UW Madison. Axitinib purchased from Selleck.

Purity & Quality Control

Choose Selective VEGFR Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description Axitinib is a multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ and c-Kit with IC50 of 0.1 nM, 0.2 nM, 0.1-0.3 nM, 1.6 nM and 1.7 nM in Porcine aorta endothelial cells, respectively.
Features Superior as second-line therapy relative to sorafenib (current standard-of-care).
Targets
VEGFR1/FLT1 [1]
(Porcine aorta endothelial cells)
VEGFR2/Flk1 [1]
(Porcine aorta endothelial cells)
VEGFR2/KDR [1]
(Porcine aorta endothelial cells)
VEGFR3 [1]
(Porcine aorta endothelial cells)
PDGFRβ [1]
(Porcine aorta endothelial cells)
0.1 nM 0.18 nM 0.2 nM 0.1 nM-0.3 nM 1.6 nM
In vitro

Axitinib could block the cellular autophosphorylation of VEGFR and VEGF-mediated endothelial cell viability, tube formation, and downstream signaling. Axitinib inhibits the proliferation of variable cell lines with IC50 of >10,000 nM (IGR-N91), 849 nM (IGR-NB8), 274 nM (SH-SY5Y) and 573 nM (non-VEGF stimulated HUVEC). [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
EoL-1-cell NXK4XGhLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTBwMECwNFUyOyEQvF2= NGPEToFUSU6JRWK=
NCI-H1703 NF\W[2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTGSJNKSzVyPUCuNFAxQTB{IN88US=> NWLwSIJtW0GQR1XS
KASUMI-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvaTWM2OD1yLkCwOlgzKM7:TR?= NI\jTYFUSU6JRWK=
CGTH-W-1 NYiwc2pUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknHTWM2OD1yLkCwO|IzKM7:TR?= NHq2OoJUSU6JRWK=
A204 NYT6cZpIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkG5TWM2OD1yLkCwPVkzKM7:TR?= NHfnbHRUSU6JRWK=
HOP-62 NFu3[YNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTBwMUC4N|Yh|ryP NWrneZd{W0GQR1XS
H-EMC-SS NYDrbZkyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nZcGlEPTB;MD6xNVAxPSEQvF2= NYrrNJBOW0GQR1XS
KU812 Mn\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDNUYpKSzVyPUCuNVY2PzdizszN MlrXV2FPT0WU
EM-2 NVryVIZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTBwMU[4NVYh|ryP NFnOPFZUSU6JRWK=
LAMA-84 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTBwMUe2OlUh|ryP MULTRW5ITVJ?
JAR M4n6Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTBwMkO5PFkh|ryP NFjkNIhUSU6JRWK=
G-361 MoPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHzco9YUUN3ME2wMlMzOzJ3IN88US=> Ml34V2FPT0WU
KG-1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTBwM{e2OFIh|ryP MlXxV2FPT0WU
BV-173 NI\LUGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTBwM{mzNkDPxE1? M2TGXXNCVkeHUh?=
K5 NEj6bmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTpOIRjUUN3ME2wMlQzOTJ5IN88US=> M1HGXnNCVkeHUh?=
MEG-01 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFn2PW1KSzVyPUCuOFI{PjFizszN NG\F[HlUSU6JRWK=
MFM-223 M2C3Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHj[|dKSzVyPUCuOFQ4PzZizszN NI\OfWFUSU6JRWK=
BE-13 NV\TRmRST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfzWnZKSzVyPUCuOVExODhizszN MYnTRW5ITVJ?
NEC8 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Moq1TWM2OD1yLkeyNVE{KM7:TR?= M4rHdHNCVkeHUh?=
SW756 Mn\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTBwOUm4OFYh|ryP NIDvbGlUSU6JRWK=
A2780 NE\EfFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTFwMEGxOFYh|ryP MYfTRW5ITVJ?
NB14 NXLSfZFNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1GxUGlEPTB;MT6wNVgxOSEQvF2= MnXtV2FPT0WU
H4 MmDPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\JUGlEPTB;MT6wOlQzOiEQvF2= M{Tue3NCVkeHUh?=
SK-OV-3 NH\zOJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHaV|dKSzVyPUGuNFY3OzNizszN Ml7PV2FPT0WU
AN3-CA Mn7iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nkOWlEPTB;MT6wPFM5QSEQvF2= NX7ESY51W0GQR1XS
A427 M{TY[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33YZWlEPTB;MT6xNFM5OSEQvF2= M{\4VnNCVkeHUh?=
ES7 NYXzUoxvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;UTWM2OD1zLkGxN|M1KM7:TR?= MWjTRW5ITVJ?
AGS NHy5cXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonsTWM2OD1zLkGxN|k2KM7:TR?= MnLnV2FPT0WU
G-402 MmDuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU[yVGlxUUN3ME2xMlE1Pjl2IN88US=> Mkn4V2FPT0WU
ES5 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfJOZdqUUN3ME2xMlE4OjR6IN88US=> NWL5N3Y{W0GQR1XS
DEL MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPIPJNCUUN3ME2xMlI2PDV5IN88US=> MUjTRW5ITVJ?
NB10 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{D5RWlEPTB;MT6zNlU2PyEQvF2= NFToeVNUSU6JRWK=
NCI-H1581 M4HLbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTDW5U4UUN3ME2xMlM6ODR{IN88US=> NGO4dIJUSU6JRWK=
D-566MG M2fxb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\aS2lEPTB;MT60NFY5OyEQvF2= MnPMV2FPT0WU
LXF-289 M{POPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDjRWlKSzVyPUGuOFM6QTZizszN NHzuRWtUSU6JRWK=
BT-549 NGLsVnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVn1WY1XUUN3ME2xMlU3QTB7IN88US=> M17WSXNCVkeHUh?=
NKM-1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvoVmVKSzVyPUGuOlA2PTZizszN NF7lXWRUSU6JRWK=
SW780 M3zMRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVH6WVZ5UUN3ME2xMlY2OTV6IN88US=> MlvDV2FPT0WU
NCI-H292 MkHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHy2SpVKSzVyPUGuOlY{QDNizszN NGLOeYFUSU6JRWK=
HMV-II M2jDdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jmTGlEPTB;MT63NFQ5QCEQvF2= M4LFNXNCVkeHUh?=
ALL-PO NVHnUld6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3zNIhJUUN3ME2xMlgxODF3IN88US=> MlTUV2FPT0WU
UACC-257 NWnsNZA5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjnTWM2OD1zLkiyNVY{KM7:TR?= M3[xW3NCVkeHUh?=
PA-1 NYC3NZF7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzveXZKSzVyPUGuPFI4OjVizszN NIKzWoFUSU6JRWK=
HD-MY-Z NF7xUFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoG1TWM2OD1zLki2NlgyKM7:TR?= MlvXV2FPT0WU
HSC-4 NGDHZZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrITWM2OD1zLkmzPFM6KM7:TR?= NUXRdplvW0GQR1XS
GCT NEXmeZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHmTI5KSzVyPUKuNFA6OTZizszN MmDrV2FPT0WU
RT-112 Mlv0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3z6eWlEPTB;Mj6xN|QzPCEQvF2= NVfkXJVuW0GQR1XS
A172 MlTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLyTWM2OD1{LkGzOlA3KM7:TR?= MmfDV2FPT0WU
HCE-T MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELuR5RKSzVyPUKuNlA2QThizszN MWPTRW5ITVJ?
YH-13 NG\QbIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlL3TWM2OD1{LkKxOlcyKM7:TR?= MYHTRW5ITVJ?
DK-MG Mof0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2W4VmlEPTB;Mj6yN|g{PCEQvF2= NHnybpdUSU6JRWK=
ACN MmPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvuPZJKSzVyPUKuNlM5PzVizszN NV;WWpVpW0GQR1XS
VA-ES-BJ MkT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTJwMkS5OVch|ryP NF\s[WNUSU6JRWK=
L-363 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfu[Y1KSzVyPUKuNlgxPjFizszN MV\TRW5ITVJ?
HuH-7 M4XOS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTJwNEKxOlUh|ryP MW\TRW5ITVJ?
A4-Fuk MnfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PhPWlEPTB;Mj60O|E3QCEQvF2= NGPx[IdUSU6JRWK=
T-24 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nvVmlEPTB;Mj60PFA{PyEQvF2= NYPjcHdnW0GQR1XS
GOTO MkD4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTmTWM2OD1{LkWzNFE{KM7:TR?= MmXqV2FPT0WU
MV-4-11 M1\2OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFSxd5JKSzVyPUKuOVkyPjlizszN MlnSV2FPT0WU
DMS-114 NVv2TmYxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLMTWM2OD1{Lk[2N|Q2KM7:TR?= NVe1dWF6W0GQR1XS
MHH-NB-11 M4PIc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrJTWM2OD1{LkewNlk6KM7:TR?= MV3TRW5ITVJ?
CHP-212 MmnMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn35TWM2OD1{LkiyNFkyKM7:TR?= MYPTRW5ITVJ?
DMS-273 MoPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPYW5dMUUN3ME2yMlkxOjB5IN88US=> MVvTRW5ITVJ?
SF295 NF3DbFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPOTWM2OD1|LkCyOVk4KM7:TR?= MYrTRW5ITVJ?
NCI-H1563 NGe1dplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfmTWM2OD1|LkG1NFA2KM7:TR?= NGDQZ|VUSU6JRWK=
NCI-H446 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3jXmI6UUN3ME2zMlIzQDB3IN88US=> MW\TRW5ITVJ?
HCC1806 MnHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXuV3RKSzVyPUOuNlc3PTdizszN NHq2WYRUSU6JRWK=
SF126 M1zLUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoS2TWM2OD1|LkOwNFE4KM7:TR?= M33i[HNCVkeHUh?=
SW982 NXzN[oVUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{L4dmlEPTB;Mz6zN|g4PSEQvF2= M{nUfnNCVkeHUh?=
ES8 MkS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLZTWM2OD1|LkO0PVk6KM7:TR?= M4rPRXNCVkeHUh?=
SCC-4 NXS3e3d3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfnTWM2OD1|LkWwN|k3KM7:TR?= NVHxPW1LW0GQR1XS
RPMI-8226 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXexenByUUN3ME2zMlYzPjF4IN88US=> M3G4enNCVkeHUh?=
EW-11 NFO1OmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTNwNkOwNlIh|ryP NGnZZlBUSU6JRWK=
COR-L105 MonlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPOZlFKSzVyPUOuOlM{OzRizszN MkDDV2FPT0WU
ES1 NVX1NVNLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnexTWM2OD1|LkizNFk1KM7:TR?= NEXwdJZUSU6JRWK=
KMOE-2 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TQcWlEPTB;Mz65NVgxQCEQvF2= NGfSO2JUSU6JRWK=
ABC-1 Mk[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fnVWlEPTB;Mz65N|kyOSEQvF2= MlXyV2FPT0WU
NCI-H526 MmryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLlNVRKSzVyPUOuPVkyOjZizszN MXHTRW5ITVJ?
HCC1395 NVv4NVR2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTjU2ZJUUN3ME2zMlk6PDh2IN88US=> NF;R[JRUSU6JRWK=
DU-145 M2Pzfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTRwMUK4NlUh|ryP M3\JUXNCVkeHUh?=
JEG-3 Mnv3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzoPXdKSzVyPUSuNVU6OTZizszN M3fJWnNCVkeHUh?=
HCC1187 NYnkT2tUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn[1TWM2OD12LkKxOVk4KM7:TR?= NU\NWlF5W0GQR1XS
LC-2-ad NWnIOnROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HLOmlEPTB;ND6yNlE4PyEQvF2= NWrMe4ZNW0GQR1XS
ONS-76 NVjGbnhwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmD5TWM2OD12LkK0NVkzKM7:TR?= NHXPfG5USU6JRWK=
CAL-27 MoO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPBXGxWUUN3ME20MlI1OzR2IN88US=> M1PTSHNCVkeHUh?=
8-MG-BA NVT0fWVPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTRwMk[2OVgh|ryP Ml;FV2FPT0WU
HGC-27 M2fJNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{SxcmlEPTB;ND6yPVY3KM7:TR?= NX;mRnlHW0GQR1XS
Hs-578-T MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjifXdKSzVyPUSuN|E1PjhizszN MlnrV2FPT0WU
EW-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXGN5JVUUN3ME20MlU{ODF2IN88US=> MmPMV2FPT0WU
SW1573 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\u[49KSzVyPUSuOVUyPjNizszN MWjTRW5ITVJ?
SNU-423 M4DRcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fCNGlEPTB;ND62NFc6KM7:TR?= NYTae|dLW0GQR1XS
HOS MmC3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUGxUFI2UUN3ME20MlY6PzdizszN MmTxV2FPT0WU
LB1047-RCC NVzuOVg2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTRwOEG0NVgh|ryP NVezSpNqW0GQR1XS
ChaGo-K-1 M{LJTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDZTWM2OD12Lki5NFQ5KM7:TR?= NIixTnFUSU6JRWK=
A3-KAW NVfjVGd5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nXSWlEPTB;ND65O|M2OiEQvF2= MVzTRW5ITVJ?
CAS-1 NGfyTmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2CxfmlEPTB;ND65PVkxQCEQvF2= NYKzSVdCW0GQR1XS
NBsusSR NXT4W3ZJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTVwMEO1NVQh|ryP MW\TRW5ITVJ?
KM12 NXjX[WNuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTVwMkm4Nlch|ryP NEfDUoFUSU6JRWK=
NCI-H1155 NIGydnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3H5TWlEPTB;NT6zPFE5PSEQvF2= NYPBVJBYW0GQR1XS
EFM-19 Mo[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLzNJBKSzVyPUWuOFE4OzdizszN M4L5UHNCVkeHUh?=
D-392MG M3zYUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXGNGRXUUN3ME21MlU4QDR7IN88US=> NEjkVJhUSU6JRWK=
JVM-3 M3\0N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHOVndKSzVyPUWuO|I{OjVizszN MmfxV2FPT0WU
EW-16 NGHkUJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrmR5JKSzVyPUWuO|U2QDNizszN M4XKb3NCVkeHUh?=
KARPAS-45 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIn3eXZKSzVyPUWuPFQ{OjVizszN NG\ZZZpUSU6JRWK=
NCI-H28 M2\ORmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjX[mM1UUN3ME21Mlg4QTF6IN88US=> M3zyVXNCVkeHUh?=
COLO-829 NVzHbnJRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXzepRKSzVyPUWuPVE2ODRizszN MU\TRW5ITVJ?
KM-H2 MonOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGm3N5hKSzVyPUWuPVI{QTVizszN NF3X[3NUSU6JRWK=
NCI-H82 NGTPXJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PvRmlEPTB;NT65Nlc4OSEQvF2= NWDWeIdpW0GQR1XS
OAW-42 Ml\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rIVWlEPTB;NT65PFgzOSEQvF2= MmDlV2FPT0WU
A704 M{XvU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnQdmxKUUN3ME22MlExPTd2IN88US=> MV;TRW5ITVJ?
NCI-H1048 NFvSbY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHqxdo9KSzVyPU[uNVA2QTlizszN NE\3T4FUSU6JRWK=
LOXIMVI MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDxZWN4UUN3ME22MlEyOjR6IN88US=> NHzOOWVUSU6JRWK=
MKN45 MoTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\5TWM2OD14LkK2NFE3KM7:TR?= NEmwVVdUSU6JRWK=
D-502MG MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M322[WlEPTB;Nj6yPFg2PyEQvF2= NWLoSYtyW0GQR1XS
HUTU-80 MkXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\6SmFnUUN3ME22MlQyPjh6IN88US=> NGLiRVdUSU6JRWK=
S-117 M1Py[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnUflFKSzVyPU[uOVAzPjdizszN MnLiV2FPT0WU
HCC1569 M37iSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXse2hKSzVyPU[uOVM4OzdizszN MVLTRW5ITVJ?
J-RT3-T3-5 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\U[IIzUUN3ME22MlU1PTd{IN88US=> NGrZV2dUSU6JRWK=
OC-314 NHLvN|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\Ie|JKSzVyPU[uPVEyPTlizszN MVfTRW5ITVJ?
SNU-449 NXzVN4tTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37kPGlEPTB;Nz6wNVA4OiEQvF2= NFPLfVFUSU6JRWK=
NCI-H720 NEP4TWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrYWVRKSzVyPUeuNVk{PDVizszN MkXqV2FPT0WU
KP-N-YS M37XeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmT3TWM2OD15LkKwO|Ih|ryP MnH3V2FPT0WU
IGROV-1 NXLzWI9TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXHZ5RRUUN3ME23MlMzOzh4IN88US=> M{XESXNCVkeHUh?=
SK-PN-DW M1y1XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml:2TWM2OD15LkS4NVUh|ryP MmmwV2FPT0WU
HCC1419 NFvoeXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnwZm1uUUN3ME23MlU{KM7:TR?= M{TMWnNCVkeHUh?=
HAL-01 M1rHNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{H0SWlEPTB;Nz62NFY1PCEQvF2= NHTyWWVUSU6JRWK=
HCC2998 MluzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTdwNkC3OFMh|ryP M4LZPXNCVkeHUh?=
SK-N-FI NEjrZ3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LURWlEPTB;Nz62N|A{OyEQvF2= MkfRV2FPT0WU
GI-ME-N NIn5WG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\TbJFKSzVyPUeuOlQ6OzRizszN NGj6VJlUSU6JRWK=
SW1088 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\vTGlEPTB;Nz62OVgzPiEQvF2= NFixNphUSU6JRWK=
IA-LM MmHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LM[mlEPTB;Nz62PFYyOyEQvF2= NHu2dZpUSU6JRWK=
SK-NEP-1 M2nKW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHyZ5pnUUN3ME23MlY6PjFizszN Mn;YV2FPT0WU
MDA-MB-415 M1;xZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTdwOEmxPFYh|ryP NEPGOG1USU6JRWK=
COLO-800 Mn24S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTdwOUS0PVIh|ryP NUjZemt{W0GQR1XS
NCI-H2228 M{LMT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHnclZUUUN3ME24MlE2Pzh|IN88US=> NInPcFBUSU6JRWK=
D-423MG NH20fZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWG1eolWUUN3ME24MlIyPzJizszN NITITYNUSU6JRWK=
TE-1 NXXNemoyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTEN3c3UUN3ME24MlQ1OzF4IN88US=> M4\YZXNCVkeHUh?=
NOS-1 NGn2OlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2WyZWlEPTB;OD61NVU{PCEQvF2= MlT3V2FPT0WU
8505C NFnx[|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPkTWM2OD16Lk[0PFI1KM7:TR?= MmX0V2FPT0WU
HEC-1 NULHTlNvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPWWVRKSzVyPUiuO|g1OzlizszN M{\qSHNCVkeHUh?=
TE-11 M1\ydWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\ETWM2OD16Lkm5OVUyKM7:TR?= M33vdHNCVkeHUh?=
CTB-1 NHrZPZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1y4WmlEPTB;OT6wNVQ{OyEQvF2= MoTNV2FPT0WU
TGBC11TKB MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTlTWM2OD17LkCyNlQyKM7:TR?= M2TaOnNCVkeHUh?=
NB17 MkPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH6zO|lKSzVyPUmuNVg5PyEQvF2= NYe0WnBEW0GQR1XS
Becker MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTQTWM2OD17LkSxPVQ1KM7:TR?= NF\INFBUSU6JRWK=
SN12C M2DLemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1uzT2lEPTB;OT60OVI{PCEQvF2= NFTlZ|NUSU6JRWK=
COLO-320-HSR M4XLd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3MTFBsUUN3ME25MlYxOjN5IN88US=> NIHNZVVUSU6JRWK=
D-283MED MlfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTlwNkOwO|Ih|ryP MlTPV2FPT0WU
D-263MG NX3FS3BYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjZR3dKSzVyPUmuPFM{QDRizszN MVTTRW5ITVJ?
MEL-JUSO M17ZU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTlwOUCxNlch|ryP NIrmRVFUSU6JRWK=
T98G M1nye2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTZZpY3UUN3ME25MlkxOjB|IN88US=> NVHNdpB[W0GQR1XS
HLE NHjDNYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHSTWM2OD17LkmwPVA6KM7:TR?= NHjqdG5USU6JRWK=
Ca9-22 NUnIbFhmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vJbWlEPTB;MUCuNFY3PSEQvF2= MnrwV2FPT0WU
OS-RC-2 MoTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlq0TWM2OD1zMD6xNFQ2KM7:TR?= MkTPV2FPT0WU
T47D MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTFyLkG1OUDPxE1? M3LFc3NCVkeHUh?=
GI-1 MonyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjsRZlGUUN3ME2xNE4{PTN|IN88US=> NXTtOGNXW0GQR1XS
NUGC-3 MnvXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTsTWM2OD1zMD60OFAzKM7:TR?= NGraTYFUSU6JRWK=
MDA-MB-361 MljXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;qXGlEPTB;MUCuOFQ{OiEQvF2= NXzYSINpW0GQR1XS
SCC-15 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTFyLkS3NVgh|ryP MlnmV2FPT0WU
KS-1 M134Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPMTWM2OD1zMD62N|AyKM7:TR?= M1;yV3NCVkeHUh?=
CAL-12T NGG0PZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTFyLk[zOlEh|ryP MnTjV2FPT0WU
OVCAR-4 NHrIRo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTFyLkewOlgh|ryP M2LGfXNCVkeHUh?=
HuP-T4 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHntfpNKSzVyPUGxMlA{OjhizszN M4PHdXNCVkeHUh?=
NCI-H358 M1fhcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\5T2lEPTB;MUGuNlY2PyEQvF2= MoXzV2FPT0WU
HO-1-N-1 Mlu5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXNTWM2OD1zMT6zN|k5KM7:TR?= MWTTRW5ITVJ?
NH-12 NHXLSJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWS5ZWU5UUN3ME2xNU42Ozd6IN88US=> NUTObGppW0GQR1XS
MOLT-4 NGO3RYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjveo1KSzVyPUGxMlU6QDVizszN NFz0fXBUSU6JRWK=
K-562 M{nibGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTFzLkeyOFgh|ryP NHy5W2hUSU6JRWK=
ES6 NFjOW3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTFzLki1PFEh|ryP M1SzTHNCVkeHUh?=
RO82-W-1 MlvXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTFzLkmwOlQh|ryP NVTNO3g{W0GQR1XS
Ramos-2G6-4C10 MmGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTFzLkmzNkDPxE1? NUfZeXF4W0GQR1XS
23132-87 M2fFSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTkUpk{UUN3ME2xNk4xQDJzIN88US=> Ml:3V2FPT0WU
A549 MnnkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTo[YJKSzVyPUGyMlMzQDVizszN NVrPTmptW0GQR1XS
NCI-H23 MkXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFO0[FBKSzVyPUGyMlUxOjZizszN M3fZUHNCVkeHUh?=
H9 NGLrS2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{m0eGlEPTB;MUKuOVU4PyEQvF2= NYLUcVdwW0GQR1XS
LB771-HNC NWPNOXBMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTF{Lke2OUDPxE1? MVjTRW5ITVJ?
QIMR-WIL Mo[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDaemRKSzVyPUGyMlgzPThizszN MnfhV2FPT0WU
HSC-3 NFv6eZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fETWlEPTB;MUKuPVI4PiEQvF2= NIGwV2pUSU6JRWK=
PFSK-1 MmHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGT6WIFKSzVyPUGyMlk2ODdizszN MWTTRW5ITVJ?
ETK-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTF|LkC3O|kh|ryP NYXhbJRQW0GQR1XS
SW1710 NEHvTo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTF|LkO2OFEh|ryP M{LD[XNCVkeHUh?=
COLO-684 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\ERWpKSzVyPUGzMlQ2PDFizszN MoT1V2FPT0WU
RPMI-7951 M1y4PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTF|LkWxN|Yh|ryP M4TPVHNCVkeHUh?=
A101D M{G1e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGK5cVNKSzVyPUGzMlU{PDlizszN NXrCRo1PW0GQR1XS
KE-37 M4LQO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TmdWlEPTB;MUOuOVg5PyEQvF2= MXfTRW5ITVJ?
SiHa M{W4[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIr2RWRKSzVyPUGzMlg{PDZizszN MnTCV2FPT0WU
NCI-H226 NYT0XWRmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\JdIl7UUN3ME2xN{45QDB6IN88US=> NEPKTFNUSU6JRWK=
DB M1frNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfQTWM2OD1zMz65PVI5KM7:TR?= NXnBdZM4W0GQR1XS
HT-1197 NEjlVJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHm4RpNKSzVyPUG0MlA5ODlizszN M3zQWXNCVkeHUh?=
SBC-5 NIjy[mtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXPOXlKSzVyPUG0MlE{PjJizszN MU\TRW5ITVJ?
VMRC-RCZ MmfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnmTWM2OD1zND61O|c1KM7:TR?= NIjNZmhUSU6JRWK=
697 NUP4XWJOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGj0OGlKSzVyPUG0MlYzPyEQvF2= MYDTRW5ITVJ?
OMC-1 Ml7rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETHcGdKSzVyPUG0Mlc5QDhizszN MkDSV2FPT0WU
SKG-IIIa MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XPemlEPTB;MUSuPFAxOSEQvF2= M3WyUXNCVkeHUh?=
DOK NVXGZVFwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DmbmlEPTB;MUSuPVk{OyEQvF2= MWTTRW5ITVJ?
NCI-H2029 NHzwfYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDqTWM2OD1zNT6zOlAzKM7:TR?= MVrTRW5ITVJ?
NCI-H2009 NVfiNlE1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTF3LkWwPVUh|ryP MlTJV2FPT0WU
LK-2 NWezXoN[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVy4co17UUN3ME2xOU43PDR7IN88US=> MmPDV2FPT0WU
NCI-H661 Mn\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPrclNYUUN3ME2xOU46ODd3IN88US=> MlTJV2FPT0WU
GT3TKB NIfGUVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDoTWM2OD1zNj6wOlc3KM7:TR?= NEKw[2RUSU6JRWK=
GP5d NYjsVZpnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLVfmdDUUN3ME2xOk4{PDJizszN NX21dphkW0GQR1XS
SK-MEL-2 MlzHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1GzWmlEPTB;MU[uOFQ5PSEQvF2= NYnLdoxZW0GQR1XS
SK-UT-1 M1zaUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljjTWM2OD1zNj61OlUh|ryP MVXTRW5ITVJ?
NB7 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTF4Lk[5O|Eh|ryP NYjaV2I4W0GQR1XS
NCI-H460 MkfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;SW5NKSzVyPUG2Mlc{OjZizszN M2X4b3NCVkeHUh?=
8305C NVz4d3FvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTVeWhKSzVyPUG2Mlc5PzdizszN MXfTRW5ITVJ?
CaR-1 NITU[mdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoS3TWM2OD1zNj64NVEyKM7:TR?= MUTTRW5ITVJ?
D-247MG NUXZcGJDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4O3WWlEPTB;MU[uPFYzPSEQvF2= NGjQPYtUSU6JRWK=
LoVo MlfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml20TWM2OD1zNj65OFg5KM7:TR?= NGD1NGtUSU6JRWK=
NCI-H2405 NYD4foVTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\xTWM2OD1zNz6xPVA5KM7:TR?= M{\JOHNCVkeHUh?=
AU565 NWLDW2c5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXLXHJUUUN3ME2xO{4zOjVizszN MVzTRW5ITVJ?
OCI-AML2 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYj2ZmpDUUN3ME2xO{42OzF5IN88US=> NWLoVJlzW0GQR1XS
22RV1 MofRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TneWlEPTB;MUeuOVg5PCEQvF2= NHjWcnVUSU6JRWK=
HT-144 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPWTWM2OD1zNz62OVk5KM7:TR?= MnnMV2FPT0WU
HuO9 NFXGO5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;ad|VKSzVyPUG3MlcxOzFizszN MYfTRW5ITVJ?
Daoy MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETCRVRKSzVyPUG3MlcyQDRizszN MmD2V2FPT0WU
SJRH30 M1freGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFn1[WtKSzVyPUG3Mlg1QDlizszN MkPrV2FPT0WU
CHL-1 M2OzZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvGU5dKSzVyPUG3MlkzPDlizszN M4n5dnNCVkeHUh?=
J82 M2TDeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLsZXVFUUN3ME2xO{46PjN3IN88US=> NUPMe|hwW0GQR1XS
COR-L23 NWnPeYFOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITqO3dKSzVyPUG4MlAxOTFizszN Mn[yV2FPT0WU
SNU-C2B M1PZ[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTkTWM2OD1zOD6yNlc3KM7:TR?= M{HOUHNCVkeHUh?=
NCI-H1770 MojES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLubnBmUUN3ME2xPE41PjF3IN88US=> NH;PTYtUSU6JRWK=
MHH-PREB-1 MknLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrSdmlKSzVyPUG4MlU3QTdizszN M4izbHNCVkeHUh?=
ES3 MnuzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3WWG5KSzVyPUG4MlU5QDNizszN NF32[|dUSU6JRWK=
MDA-MB-231 NW\UZZVJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3X4N2lEPTB;MUiuOlUxOiEQvF2= NFjid|RUSU6JRWK=
MN-60 NILLVHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTF7LkC1PVIh|ryP MmntV2FPT0WU
EPLC-272H NV;qb5VtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHT[VZ{UUN3ME2xPU4{PzB6IN88US=> NH\6XGxUSU6JRWK=
SW948 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfTXmdMUUN3ME2xPU4{QTN2IN88US=> NGDKeWpUSU6JRWK=
MOLT-13 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HGRmlEPTB;MUmuOFU1PiEQvF2= MYjTRW5ITVJ?
HL-60 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULZZ3lnUUN3ME2yNE4zOTRzIN88US=> NVS5eW5UW0GQR1XS
CP50-MEL-B M33UNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzCTWM2OD1{MD60O|Q5KM7:TR?= NVzMZ2RKW0GQR1XS
NTERA-S-cl-D1 NXTiOZVwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4n2WGlEPTB;MkCuOFk4QCEQvF2= M4nuOHNCVkeHUh?=
KINGS-1 M3P0W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXixcpFqUUN3ME2yNE44QTZ5IN88US=> NE\H[nRUSU6JRWK=
DOHH-2 NGXQSVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XL[WlEPTB;MkCuPVA3KM7:TR?= M2HkVHNCVkeHUh?=
BB65-RCC NFLXNZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHX2VGNKSzVyPUKwMlkzQDVizszN MlHNV2FPT0WU
NB12 M1WwXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvDTWM2OD1{MT6wN|k1KM7:TR?= NYHUV4t2W0GQR1XS
KY821 NVTl[YZHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWS4V|NTUUN3ME2yNU42QDJizszN MWjTRW5ITVJ?
PSN1 MkHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEe4[3dKSzVyPUKxMlY1PTNizszN NHjvNIJUSU6JRWK=
EGI-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvhTWM2OD1{MT63OFU1KM7:TR?= M{TQO3NCVkeHUh?=
CTV-1 M4\Tbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTJ{LkOwN|Eh|ryP MYTTRW5ITVJ?
TI-73 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{L1PWlEPTB;MkKuN|Q6QCEQvF2= NVztTWN[W0GQR1XS
LCLC-103H MkG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTJ{LkS3OVIh|ryP NFHlSWRUSU6JRWK=
D-542MG MlvqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PFOGlEPTB;MkKuOVU2QCEQvF2= NIHHfm1USU6JRWK=
ATN-1 M4XQR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLNTWM2OD1{Mj62OFM6KM7:TR?= M{T5T3NCVkeHUh?=
SK-MEL-1 M1PpZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTJ{LkizOlgh|ryP MVjTRW5ITVJ?
HDLM-2 NHrOeFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjsTWM2OD1{Mz6xOFc5KM7:TR?= MUPTRW5ITVJ?
UM-UC-3 NIjZO4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrYRY5qUUN3ME2yN{4yQTR2IN88US=> MVvTRW5ITVJ?
NCI-H1573 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnCdlNQUUN3ME2yN{41PjhzIN88US=> Mnj3V2FPT0WU
NCI-H520 M3LWNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjkd3NKSzVyPUKzMlQ6PDhizszN NWLPTmJGW0GQR1XS
ESS-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1v0UGlEPTB;MkOuPFA2QSEQvF2= M4jJSHNCVkeHUh?=
COR-L88 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TvfGlEPTB;MkOuPVQ4PSEQvF2= NXXRN|hRW0GQR1XS
TGBC24TKB MkfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\iTWM2OD1{ND6wN|EzKM7:TR?= M3zxdHNCVkeHUh?=
HCC1937 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTJ2LkGg{txO NGj5boFUSU6JRWK=
RS4-11 NEnEbVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1L6cmlEPTB;MkSuNVQzKM7:TR?= NHPTZ4FUSU6JRWK=
HCC38 Mm\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX[3e3NXUUN3ME2yOE4zOzl2IN88US=> M2W2W3NCVkeHUh?=
RPMI-2650 NF;UdllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTJ2Lk[xOlIh|ryP MXvTRW5ITVJ?
P12-ICHIKAWA MoTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTJ2Lk[yOVgh|ryP M4njT3NCVkeHUh?=
YAPC NUf4eYgxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX[4c5BjUUN3ME2yOE45OjF2IN88US=> M{XRSXNCVkeHUh?=
NB13 NYPzR|R1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7NXYlHUUN3ME2yOU4zPjFzIN88US=> MmHNV2FPT0WU
SK-N-AS NUH1fFdXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHLTWM2OD1{NT64OVg1KM7:TR?= MlPPV2FPT0WU
SK-N-DZ MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HHWGlEPTB;Mk[uNFQ6KM7:TR?= NYnWZYdGW0GQR1XS
LS-411N NYn4SJlWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTzW2VIUUN3ME2yOk4zODN6IN88US=> Mn7nV2FPT0WU
NCI-H810 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPBfo9KSzVyPUK2MlMyOTJizszN NUixe4NsW0GQR1XS
NCI-SNU-1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTJ4LkW0OVQh|ryP M4ThZXNCVkeHUh?=
HH NUjh[I9CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTJ4LkW1Nlkh|ryP NEnpUpVUSU6JRWK=
U-2-OS NXO2UZFPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrRTWM2OD1{Nj63N|gzKM7:TR?= M1HMcXNCVkeHUh?=
SF539 NIX2V4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2[xOWlEPTB;Mk[uPFAyQCEQvF2= NFGyeJBUSU6JRWK=
NCI-H2052 M3e1[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfNd5hKSzVyPUK3MlA5PiEQvF2= NWPPUZFHW0GQR1XS
A673 NUewUlY6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTJ5LkKxNFIh|ryP NVnUXIRjW0GQR1XS
WM-115 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHy4WldKSzVyPUK3Mlc4PjdizszN MkT6V2FPT0WU
SW48 M1G1emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHBOG82UUN3ME2yO{45ODB3IN88US=> MmntV2FPT0WU
NOMO-1 MnG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3md5hKSzVyPUK3Mlg2OzJizszN MWHTRW5ITVJ?
PC-3 M2HDe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHG4WmpKSzVyPUK3Mlg6PDFizszN NYn1e4ZnW0GQR1XS
UMC-11 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTJ5LkmzOFMh|ryP MV7TRW5ITVJ?
U-118-MG MojPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPKTWM2OD1{OD6wNVI{KM7:TR?= MUPTRW5ITVJ?
NCI-H2452 MmLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnGVYlKSzVyPUK4MlA5OjJizszN M1v4eXNCVkeHUh?=
CAMA-1 MkC1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1v1bGlEPTB;MkiuPFU3PCEQvF2= Mny4V2FPT0WU
MC-IXC MmHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33w[WlEPTB;MkmuNlM3PiEQvF2= NUHaOGd2W0GQR1XS
ES4 NWD0emZCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rCXmlEPTB;MkmuN|E4OiEQvF2= NWi4OoNSW0GQR1XS
BHT-101 MoHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDWcoVKSzVyPUK5MlMzOSEQvF2= NHjxXXZUSU6JRWK=
KP-4 M3\BW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{f1[WlEPTB;MkmuOVE3KM7:TR?= NXnRfXF5W0GQR1XS
CAL-54 NILkT2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\JOVNKSzVyPUK5MlU1PDVizszN M3TaXXNCVkeHUh?=
5637 MlLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTJ7Lk[0NlEh|ryP NWnSfYJ1W0GQR1XS
MOLT-16 M3m1Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH75R2dKSzVyPUK5MlczPjlizszN MnvEV2FPT0WU
Ca-Ski NGrKfphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDRTWM2OD1{OT65OFYh|ryP Mo\jV2FPT0WU
AsPC-1 MlLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PhPGlEPTB;M{CuNFIyOiEQvF2= MWDTRW5ITVJ?
MSTO-211H NEjXPHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXewXFhJUUN3ME2zNE4yPSEQvF2= NIf5[lFUSU6JRWK=
L-428 NFLZeI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTNyLkSwOUDPxE1? MonmV2FPT0WU
SW1463 M{Xzc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLrO29KSzVyPUOwMlU{QDNizszN MUTTRW5ITVJ?
NCI-H1648 M4LIeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTNyLkW1O|Qh|ryP NX6xSmF7W0GQR1XS
CAKI-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jRfmlEPTB;M{CuO|cxOiEQvF2= M4fOe3NCVkeHUh?=
YKG-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTnTWM2OD1|MT6wNlY{KM7:TR?= NF;OS5JUSU6JRWK=
A2058 NIXWV2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HZfWlEPTB;M{GuNVE3PCEQvF2= MYXTRW5ITVJ?
A375 NV7uUJZuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;lUGlEPTB;M{GuNVY6PiEQvF2= NGS2dlFUSU6JRWK=
SNB75 M{nRfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nDRmlEPTB;M{GuNlQ{PSEQvF2= NWPKO29tW0GQR1XS
SK-HEP-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonhTWM2OD1|MT60NlcyKM7:TR?= M3LxTHNCVkeHUh?=
ME-180 NVLNbndnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTNzLk[1OFIh|ryP MX7TRW5ITVJ?
NCI-H209 NFP3XG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2K2[GlEPTB;M{GuPFI1PyEQvF2= M4T4dnNCVkeHUh?=
HC-1 MmrGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTN{LkG0OFYh|ryP MW\TRW5ITVJ?
LB373-MEL-D NV7yZnpET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7xcJlDUUN3ME2zNk4yQTdzIN88US=> NV\4WZIzW0GQR1XS
SNU-387 NGfHdJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13KZmlEPTB;M{KuN|E6OSEQvF2= M1K2e3NCVkeHUh?=
C32 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{WzNmlEPTB;M{KuN|M2OyEQvF2= NYi4[VV7W0GQR1XS
EW-13 NUjodW5VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTN{Lkm0NFgh|ryP NYPmcoxqW0GQR1XS
BFTC-905 MoHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTN|LkWxN|Yh|ryP NGfiPGRUSU6JRWK=
NCI-H1299 NYTFOnhET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrp[YxKSzVyPUOzMlU3OjFizszN MWrTRW5ITVJ?
LU-135 MlfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XhUmlEPTB;M{OuPFAyKM7:TR?= M4DJOHNCVkeHUh?=
NCI-H2122 NWjpb3Y6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13OV2lEPTB;M{OuPVk3PiEQvF2= MYPTRW5ITVJ?
SK-LMS-1 NYK4VXB2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILETGtKSzVyPUO0MlQyODdizszN M{XhTXNCVkeHUh?=
LNCaP-Clone-FGC MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkKzTWM2OD1|ND64OVE2KM7:TR?= Mm\TV2FPT0WU
NCI-H1092 NViwVlFCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;OTWM2OD1|NT6yO|Q4KM7:TR?= MYPTRW5ITVJ?
MS-1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXS1TW85UUN3ME2zOU4{ODN6IN88US=> MXLTRW5ITVJ?
KYSE-510 M4TUR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDoTWM2OD1|NT61NFQzKM7:TR?= M2jpWnNCVkeHUh?=
NCI-H1793 M33S[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4L4UWlEPTB;M{WuOlU1PSEQvF2= NIH3XWhUSU6JRWK=
MIA-PaCa-2 M3m2U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrZTWM2OD1|Nj6wOFk3KM7:TR?= NHu0T5JUSU6JRWK=
EW-22 Mnf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHL[pBRUUN3ME2zOk41ODd{IN88US=> M3vqe3NCVkeHUh?=
IGR-1 MneyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTN4LkixPFQh|ryP MXHTRW5ITVJ?
HT-1080 Mnz4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXTPHRKSzVyPUO3MlEzPSEQvF2= NYS3SXoxW0GQR1XS
M14 NWXBWXFRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfOfW5kUUN3ME2zO{4yPjR{IN88US=> NEC1T3FUSU6JRWK=
786-0 M3G2TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2W4UGlEPTB;M{euNlc6PCEQvF2= NYHtb3lKW0GQR1XS
MZ2-MEL NVTGUYxnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rUTGlEPTB;M{euOFUxOSEQvF2= NIDvPJFUSU6JRWK=
NCI-H510A MnLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\XTWM2OD1|Nz65OFEzKM7:TR?= MnTaV2FPT0WU
LAN-6 NYTEfY5XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fIeGlEPTB;M{euPVU5OiEQvF2= NX;vcoVwW0GQR1XS
SW620 NVTwUZZtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYC4NoZ5UUN3ME2zPE41QTd2IN88US=> NFnifoRUSU6JRWK=
LB2241-RCC NHrjVG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorITWM2OD1|OT64NlA2KM7:TR?= M4j6c3NCVkeHUh?=
Detroit562 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTRyLkGyOlgh|ryP NHzIZnRUSU6JRWK=
HN NIHVfHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLWTWM2OD12MD6xO|gzKM7:TR?= NV7l[4NsW0GQR1XS
HCT-15 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTRyLkW5NFch|ryP NGT4SJRUSU6JRWK=
C2BBe1 NWH2bJNLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDZPY8yUUN3ME20NE46OTV5IN88US=> M4PTR3NCVkeHUh?=
A498 MnvZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjCTWM2OD12MT6zNFE2KM7:TR?= MXnTRW5ITVJ?
SK-MEL-24 NVTT[|RbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTRzLkS3NlUh|ryP Mk\HV2FPT0WU
OVCAR-5 NFL5NlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUG5PGE1UUN3ME20NU44PzZ5IN88US=> MVXTRW5ITVJ?
NCI-H1792 NWizU5hiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPNeJJLUUN3ME20NU46QDJzIN88US=> MYjTRW5ITVJ?
KOSC-2 M1TyXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHX4TZpKSzVyPUSyMlI3QTlizszN MoDrV2FPT0WU
Mo-T M4KzSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7qW2RKSzVyPUSyMlg6PThizszN MV;TRW5ITVJ?
CFPAC-1 NYr3WpVyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\xb|VKSzVyPUSzMlQ6PDRizszN M1zlW3NCVkeHUh?=
CAL-51 M{jOdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYr3cY51UUN3ME20N{42PjB3IN88US=> NYPrUINvW0GQR1XS
RH-18 M1;jXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fBNGlEPTB;NEOuPFA2KM7:TR?= NHWyUVZUSU6JRWK=
EC-GI-10 NX\5SXRNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;nfZNKSzVyPUSzMlg{PDdizszN MVfTRW5ITVJ?
HSC-2 NGnXZZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3O4bWlEPTB;NESuNFA6KM7:TR?= NFToelBUSU6JRWK=
ML-2 NV;jXZJrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI[yPHVKSzVyPUS1MlI3OjFizszN NF3G[ItUSU6JRWK=
KNS-81-FD NFLWPY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnTPJBKSzVyPUS1Mlc{PjVizszN MUXTRW5ITVJ?
NB6 NWXNe|BNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTR4LkGxNUDPxE1? M2DlcHNCVkeHUh?=
MCF7 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rGXGlEPTB;NE[uOVU{OyEQvF2= NULKNYVuW0GQR1XS
P30-OHK MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{joeWlEPTB;NE[uPFEyPyEQvF2= Mm\NV2FPT0WU
BPH-1 NVjPe48xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37mNWlEPTB;NE[uPVgxPSEQvF2= MkW3V2FPT0WU
U251 NWrBbHJWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTR4Lkm5OEDPxE1? MVfTRW5ITVJ?
MKN1 M{fRTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{m1S2lEPTB;NEeuOVE{PyEQvF2= NFLWR21USU6JRWK=
A431 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTR5LkizN|gh|ryP M1rCPXNCVkeHUh?=
C8166 NXHZ[2x2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfq[|FKSzVyPUS5MlIxOzlizszN M4HRbHNCVkeHUh?=
HEL MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlKwTWM2OD12OT60NFY1KM7:TR?= MVPTRW5ITVJ?
RMG-I MlXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTR7LkS0OFQh|ryP MkjJV2FPT0WU
CAL-72 NELOSmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4O0[GlEPTB;NEmuOlA4PSEQvF2= NUK4eHE{W0GQR1XS
SW962 M4SycWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfueWJKSzVyPUS5Mlk{OzJizszN M1PH[nNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo Axitinib exhibits primary inhibition to orthotopically transplanted models such as M24met (melanoma), HCT-116 (colorectal cancer), and SN12C (renal cell carcinoma). [1] Axitinib delays the tumor growth with 11.4 days compared to the controls (p.o. 30 mg/kg) and decreases the Mean Vessels Density (MVD) to 21, compared to 49 in controls, in IGR-N91 flank xenografts. [2] Axitinib significantly inhibits growth and disrupts tumor microvasculature in BT474 breast cancer model at 10-100 mg/kg. [3] Axitinib has shown single-agent activity in variable tumors, including renal cell carcinoma, thyroid cancer, non-small cell lung cancer, and melanoma.

Protocol

Kinase Assay:

[1]

+ Expand

Cellular receptor kinase phosphorylation assay:

Porcine aorta endothelial (PAE) cells, which overexpress full-length VEGFR2, PDGFRβ, Kit, and NIH-3T3, which overexpress murine VEGFR2 (Flk-1) or PDGFRα, are generated. The 96-well plates are coated with 100 μL/well of 2.5 μg/mL anti-VEGFR2 antibody, 0.75 μg/mL anti-PDGFRβ antibody, 0.25 μg/mL anti-PDGFRα antibody, 0.5 μg/mL anti-KIT antibody, or 1.20 μg/mL anti-Flk-1 antibody to prepare ELISA capture plates. Then phosphorylation of RTK is measured by ELISA.
Cell Research:

[2]

+ Expand
  • Cell lines: HUVEC, SH-SY5Y, IGR-N91 and IGR-NB8 cells
  • Concentrations: 1 nM - 10 μM
  • Incubation Time: 72 hours
  • Method:

    Cells are seeded in a 96-well plate at a density of 5 × 104 and cultured for 24 hours. Axitinib is added to the cells at concentrations ranging from 1 nM to 10 μM. Cell viability is measured after 72 hours by MTS tetrazolium substrate and IC50 values are calculated.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: BT474 breast cancer cells are implanted subcutaneously into Immune-deficient female mice (Nu/nu; age 8-12 weeks).
  • Formulation: 0.5% carboxymethylcellulose (CMC)
  • Dosages: 10, 30 or 100 mg/kg
  • Administration: Oral daily
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 35 mg/mL (90.56 mM) warming
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 0.5% CMC 30 mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 386.47
Formula

C22H18N4OS

CAS No. 319460-85-0
Storage powder
in solvent
Synonyms AG 013736

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02156895 Not yet recruiting Advanced Renal Cell Carcinoma Pfizer June 2017 --
NCT02782403 Not yet recruiting Leukemia M.D. Anderson Cancer Center|Pfizer September 2016 Phase 1|Phase 2
NCT02859012 Recruiting Recurrent ACC, metastaticACC, Unreaectable ACC Seoul National University Hospital September 2016 Phase 2
NCT02853331 Recruiting Renal Cell Carcinoma Merck Sharp & Dohme Corp. September 2016 Phase 3
NCT02762513 Recruiting Squamous Cell Carcinoma of the Head and Neck University of Michigan Cancer Center|National Comprehensive Cancer Network August 2016 Phase 2
NCT02684006 Recruiting Renal Cell Cancer Pfizer March 2016 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

VEGFR Signaling Pathway Map

VEGFR Inhibitors with Unique Features

Related VEGFR Products

Tags: buy Axitinib | Axitinib supplier | purchase Axitinib | Axitinib cost | Axitinib manufacturer | order Axitinib | Axitinib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID